ELMOD2

Across TCGA pan-cancer cohorts, ELMOD2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ELMOD2 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ELMOD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ELMOD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where ELMOD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.893	0.445	<.001	52	view →
HNSC	DFS	Median	II,III,IV	0.805	0.538	.002	19	view →
LUAD	DFS	Median	All	0.500	0.839	.016	16	view →
PDAC	OS	Median	III,IV	0.571	0.920	.007	11	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
LSCC	OS	Median	II,III,IV	1.000	0.890	.032	2	view →
GBM	OS	Tertile	All	0.806	0.892	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ELMOD2–CCRCC (OS)

Open the CCRCC breakdown →